What is the role of creatinine kinase isoenzyme-MB (CK-MB) monitoring in thrombolytic therapy for pulmonary embolism (PE)?

Updated: Aug 04, 2021
  • Author: Wanda L Rivera-Bou, MD, FAAEM, FACEP; Chief Editor: Erik D Schraga, MD  more...
  • Print


Bozbay et al suggested that levels of creatinine kinase isoenzyme-MB (CK-MB) may be used as a prognostic marker for inpatients with PE treated with tPA. [34] In their study of 148 patients with acute PE who received tPA, those with high CK-MB levels at admission (>31.5 U/L) had higher rates of inpatient mortality (37.1%) than those with low CK-MB levels at admission (1.7%). Long-term outcomes were similar for the two groups with regard to recurrent PE, major/minor bleeding, and mortality. [34]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!